Litcius/Paper detail

Co-encapsulation of paclitaxel and 5-fluorouracil in folic acid-modified, lipid-encapsulated hollow mesoporous silica nanoparticles for synergistic breast cancer treatment

Huanli Yin, Qi Yan, Yuan Liu, Lan Yang, Yang Liu, Yujie Luo, Tianyu Chen, Ningxi Li, Min Wu

2022RSC Advances28 citationsDOIOpen Access PDF

Abstract

in a simulated tumor microenvironment. Moreover, the inhibitory effect of the dual-loaded nanoparticles was significantly better than that of the free drugs, suggesting that the composite nanosystem has the potential to selectively target tumor sites and perform the synergistic effect of PTX and 5-FU, while reducing their toxic effects on normal tissues.

Topics & Concepts

PaclitaxelChemistryMesoporous silicaFolic acidNanoparticleSolid lipid nanoparticleFolate receptorDrug deliveryMicroemulsionMesoporous materialControlled releaseLiposomeMicelleNanotechnologyPharmacologyBiophysicsCancer cellMaterials scienceBiochemistryAqueous solutionCancerOrganic chemistryMedicineCatalysisBiologyPulmonary surfactantInternal medicineNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsCancer, Lipids, and Metabolism
Co-encapsulation of paclitaxel and 5-fluorouracil in folic acid-modified, lipid-encapsulated hollow mesoporous silica nanoparticles for synergistic breast cancer treatment | Litcius